- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Scorpion venom stings cancer
While the sting of most scorpions is nonlethal to humans, it's not usually considered health-enhancing either. But the venom could actually prove lifesaving.
While the sting of most scorpions is nonlethal to humans, it's not usually considered health-enhancing either. But the venom could actually prove lifesaving.
Dr. James M. Olson and colleagues at the Fred Hutchinson Cancer Research Center in Seattle attached the peptide chlorotoxin to Cy5.5, a fluorescent molecule that emits near-infrared light. Chlorotoxin, a component of scorpion venom, preferentially binds to cancer cells (Cancer Res 2007;67:6882-6888).
The probe lit up malignant gliomas, medulloblastomas, prostate cancer, intestinal cancer, and sarcomas. Brain tumors as small as 1 mm in diameter and as few as 200 metastatic prostate cancer cells were visualized.
The unique contrast agent shows promise for imaging melanoma and skin, esophageal, cervical, lung, and colon cancers. It binds to cancer cells within minutes after injection, but its signal can be detected for 14 days. Iron oxide-based nanoparticles coated with chlorotoxin imaging are being developed for use with MR.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
